Soligenix CEO Highlights Critical Phase 3 Data Readout for HyBryte in CTCL Treatment
Event summary
- Soligenix CEO Dr. Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL).
- The blinded aggregate response rate at the 50-patient mark was 48%, significantly higher than the conservatively assumed 25%.
- Interim analysis this quarter could lead to early trial termination for overwhelming efficacy or continuation to 80 patients.
- Top-line results for the Phase 3 study are anticipated in the second half of 2026, potentially paving the way for commercialization and partnerships.
The big picture
Soligenix's Phase 3 FLASH2 study for HyBryte™ represents a critical inflection point for the company, with interim data suggesting strong efficacy in treating CTCL. The study's outcome could de-risk the development program and position Soligenix for potential commercialization and strategic partnerships. The biopharmaceutical sector is closely watching rare disease treatments, particularly those with strong clinical data supporting regulatory approvals.
What we're watching
- Clinical Efficacy
- How the interim analysis results will impact the trial's continuation and potential early termination for efficacy.
- Commercial Outlook
- Whether successful Phase 3 results will accelerate commercialization and partnership opportunities for HyBryte™.
- Regulatory Pathway
- The pace at which Soligenix can secure regulatory approvals following positive Phase 3 data.